Intersouth Partners
Intersouth Partners is a venture capital firm based in Durham, North Carolina, with a history dating back to 1985. It manages $780 million across seven funds, making it the largest venture capital fund in North Carolina and one of the largest in the Southeast. The firm invests in technology and life science sectors, leveraging extensive industry expertise and a broad network to support early-stage companies. Intersouth has invested in over 100 private companies, fostering innovation and entrepreneurship in the region. Currently, it is not making new investments.
Industries
Nr. of Employees
small (1-50)
Intersouth Partners
Patents
Method and system for consistent, repeatable, and safe cryospray treatment of airway tissue
US-11963709-B2
View DetailsMethod and system for consistent, repeatable, and safe cryospray treatment of airway tissue
US-9867648-B2
View Details
Method and system for consistent, repeatable, and safe cryospray treatment of airway tissue
US-11963709-B2
View DetailsMethod and system for consistent, repeatable, and safe cryospray treatment of airway tissue
US-9867648-B2
View DetailsServices
Providing capital to early‑stage and growth companies across technology and life science sectors, including leading and co‑leading financing rounds.
Board membership, governance guidance and temporary executive leadership to support operational transitions and growth.
Seed funding, office incubation and mentoring for scientific founders and early teams to develop business plans, licensing and initial commercialization.
Advisory and execution support for mergers, acquisitions, public offerings and similar exit transactions, including negotiating and coordinating deal execution.
Support for therapeutic companies advancing programs through discovery and clinical trial phases, including helping assemble financing and strategic partners for development.
Providing capital to early‑stage and growth companies across technology and life science sectors, including leading and co‑leading financing rounds.
Board membership, governance guidance and temporary executive leadership to support operational transitions and growth.
Seed funding, office incubation and mentoring for scientific founders and early teams to develop business plans, licensing and initial commercialization.
Advisory and execution support for mergers, acquisitions, public offerings and similar exit transactions, including negotiating and coordinating deal execution.
Support for therapeutic companies advancing programs through discovery and clinical trial phases, including helping assemble financing and strategic partners for development.
Expertise Areas
- Venture capital and fund management
- Early‑stage investing and seed financing
- Portfolio company governance and board leadership
- Technology assessment and commercialization
Key Technologies
- Monoclonal antibody therapeutics
- Genomics and DNA sequencing
- Bioinformatics
- Drug discovery and preclinical development
News & Updates
Accipiter developed software solutions for targeted online advertising, leading to a significant exit after being acquired by CMGI, with the transaction value increasing from $35 million to over $500 million due to strategic share considerations.
Insmed, focused on therapeutics for Type II adult onset diabetes, was supported by Intersouth through multiple funding rounds and a reverse merger into Celtrix Pharmaceuticals, reaching a peak market capitalization of $1.3 billion.
OpenSite, an auction software company, raised $6 million with Intersouth's help, and later $26 million, before being acquired by Siebel Systems for $550 million.
Founded based on technology from Duke University, Cellective focused on monoclonal antibodies for autoimmune diseases, raised $27.5 million in Series A, and was acquired by MedImmune.
A biotech company spun out of Duke University, Sphinx was the first biotech IPO in North Carolina, raising $75 million, and contributed to the region's biotech growth.
A genomics company founded by ex-Novartis managers, went public with a $42 million IPO in 2000 after Intersouth's seed investment and leadership.
Accipiter developed software solutions for targeted online advertising, leading to a significant exit after being acquired by CMGI, with the transaction value increasing from $35 million to over $500 million due to strategic share considerations.
Insmed, focused on therapeutics for Type II adult onset diabetes, was supported by Intersouth through multiple funding rounds and a reverse merger into Celtrix Pharmaceuticals, reaching a peak market capitalization of $1.3 billion.
OpenSite, an auction software company, raised $6 million with Intersouth's help, and later $26 million, before being acquired by Siebel Systems for $550 million.
Founded based on technology from Duke University, Cellective focused on monoclonal antibodies for autoimmune diseases, raised $27.5 million in Series A, and was acquired by MedImmune.
A biotech company spun out of Duke University, Sphinx was the first biotech IPO in North Carolina, raising $75 million, and contributed to the region's biotech growth.
A genomics company founded by ex-Novartis managers, went public with a $42 million IPO in 2000 after Intersouth's seed investment and leadership.